Remission-driven discontinuation shapes the observed duration of emicizumab in acquired hemophilia A. Comment on: “Short-term emicizumab in patients with acquired hemophilia A”

Manuel Rodríguez López; Michael Calviño Suarez

doi:10.3324/haematol.2026.301818

Comments

Remission-driven discontinuation shapes the observed duration of emicizumab in acquired hemophilia A. Comment on: “Short-term emicizumab in patients with acquired hemophilia A”

Manuel Rodríguez López
Michael Calviño Suarez

Department of Hematology and Hemotherapy, Hospital Universitario Álvaro Cunqueiro, EOXI Vigo, Instituto de Investigación Sanitaria Galicia-Sur (IISGS), Galiza

Department of Hematology and Hemotherapy, Complejo Hospitalario Universitario A Coruña, Galiza

Haematologica Early view Aug 27, 2026 https://doi.org/10.3324/haematol.2026.301818

Abstract

Not available.

Figures & Tables

Article Information

Early view : Comments

DOI

https://doi.org/10.3324/haematol.2026.301818

Published

2026-08-27

Published By

Ferrata Storti Foundation, Pavia, Italy

Print ISSN

0390-6078

Online ISSN

1592-8721

Copyright & Usage

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Article Usage

Online Views

136

PDF Downloads

44

No Data

PlumX

Remission-driven discontinuation shapes the observed duration of emicizumab in acquired hemophilia A. Comment on: “Short-term emicizumab in patients with acquired hemophilia A”

Abstract

Figures & Tables

Article Information

Article Usage

Download Citation

Navigate

For Authors

For Reviewers

For Advertisers

Education

Privacy

More